Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma presented promising data from its Phase 2 study of imlifidase at the 2025 PNS Annual Meeting, highlighting its potential in treating Guillain-Barré Syndrome (GBS). The study demonstrated that imlifidase, when used with standard intravenous immunoglobulin, was safe and well-tolerated, offering significant insights into improving patient care for GBS, a condition with limited treatment options.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company focused on developing innovative treatments for rare immunological conditions. Based in Lund, Sweden, the company specializes in IgG-cleaving enzyme technology to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 198,611
Current Market Cap: SEK1.72B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.